NeoGenomics Immuno-Oncology Profiling Tests
NeoGenomics has launched an expansion of its NeoTYPE cancer profiles to include Tumor Mutation Burden (TMB) and microsatellite instability (MSI) testing. TMB is a new genomic biomarker that is designed to predict response to checkpoint inhibitor immunotherapies targeting the PD-1 and PD-L1 proteins. The TMB tests will be available on a standalone basis, and in combination with the various cancer-specific NewTYPE tests, the company said. MSI testing will be offered to patients to identify metastatic solid tumors that are MSI-high or mismatch repair deficient (MMR). They company is offering MSI testing as a result of the FDA's recent approval of Merck's Keytruda drug to treat patients identified to have MSI-high or MMR tumors.